Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Oppenheimer Initiates Coverage On Corebridge Financial with Outperform Rating, Announces Price Target of $30

Oppenheimer analyst Chris Kotowski initiates coverage on Corebridge Financial (NYSE:CRBG) with a Outperform rating and announces Price Target of $30.
byBenzinga Newsdesk
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Oppenheimer analyst Chris Kotowski initiates coverage on Corebridge Financial (NYSE:CRBG) with a Outperform rating and announces Price Target of $30.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

GSK Announced Blenrep DREAMM-3 Phase III Did Not Meet Primary Endpoint of Progression-free Survival

By Charles Gross
November 7, 6:05 AM
GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin) monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM), did not meet its primary endpoint of progression-free survival (PFS).

GSK